Immunohelix is a biotechnology startup founded in 2022 that focuses on immuno-modulation through cell-specific delivery of oligonucleotide drugs to antigen-presenting cells. The company is currently working on groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers and has completed IND enabling studies. The last investment round of the company was a significant $12.40M Series C investment that took place on 09 January 2019. The investors participating in this round included Mitsui Global Investment, INCJ, Mitsui & Co, and P&E Directions.
Immunohelix
Founded 2022
2 employees
Series C
Total: $21.40M
Biotechnology, Health Care +1
General Information
Company Name
Immunohelix
Founded Year
2022
Employees
2
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series C
BounceWatch is an independent company data service, not affiliated with Immunohelix. To contact Immunohelix, visit napajen.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Immunohelix compare?
A PDF of Immunohelix and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Immunohelix soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Immunohelix
Business keywords: immunomodulation, oligonucleotide drugs, antigen presenting cells, anti-GVHD drug, hematopoietic stem cell transplantation, hematological cancers, pharmaceutical company
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | $12.40M | 4 |
|
09 Jan 2019 |
| Series A | $9.00M | 1 |
|
03 Feb 2014 |
Immunohelix Alternatives & Competitors
View All Alternatives
Immunohelix vs
Genenta is a clinical stage immuno-oncology company
Post-IPO Secondary
25 employees
Biotechnology, Health Care
Immunohelix vs
Cornerstone Pharmaceuticals
United States
Rare Science. Rare Compassion. Rare Solutions.
11 employees
Biotechnology, Pharmaceutical
Immunohelix vs
Priothera SAS
France
Adding Quality Years of Life
Debt Financing
21 employees
Biotechnology, Health Care
FAQ About Immunohelix
A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.
Immunohelix was founded in 2022.
Immunohelix operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on immunomodulation, oligonucleotide drugs, antigen presenting cells and anti-GVHD drug.
Immunohelix has approximately 2 employees.
Immunohelix has completed 2 funding rounds, raising a total of $21.40M. The latest funding stage is Series C.
Top alternatives and competitors to Immunohelix include Genenta Science (Nasdaq: GNTA), Cornerstone Pharmaceuticals, Priothera SAS, Appia Bio, ACM Biolabs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunohelix and Genenta Science (Nasdaq: GNTA) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Immunohelix, https://bouncewatch.com/company/immunohelix, updated 27 December 2024. When citing, please name BounceWatch and link this page.
